CMT1H

FBLN5 | 2020

What Is CMT1H?

CMT1H is a type of CMT caused by mutations in the FBLN5 gene. This gene provides instructions for producing fibulin-5, a protein involved in the structure and elasticity of connective tissue, as well as in interactions between Schwann cells and the extracellular matrix.

CMT1H is autosomal dominant, meaning that just one of the gene’s two copies needs a mutation to cause this subtype.

Clinical Features

Symptoms typically begin in adulthood (late onset), with a median age of onset in the late 30s. Both upper and lower limbs are involved, though weakness and muscle atrophy are often more pronounced in the lower limbs. Disease progression is generally slow.

CMT1H symptoms may include:

  • Symptoms typically begin in adulthood
  • Weakness in the feet and lower legs
  • Muscle atrophy, more pronounced in the lower limbs
  • Walking difficulty and gait impairment
  • Reduced sensation
  • Reduced deep tendon reflexes
  • Unpleasant sensory sensations in the upper limbs
  • Foot deformities
  • Progressive involvement of the hands and forearms
  • Rare features such as joint hypermobility, hyperelastic skin, or age-related macular degeneration
  • Additional symptoms not listed here

Disease Course

CMT1H shows variability in severity and progression. Some individuals experience a relatively mild course, while others develop a more severe presentation. Some may experience symptoms similar to Ehlers-Danlos Syndrome (EDS). Progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
CMT1H

Classification
CMT1

Neuropathy Type
Demyelinating

Inheritance Pattern
autosomal dominant

Genetic Context

HGNC-Approved Gene Symbol
FBLN5

Gene Full Name
fibulin 5

HGNC Gene Alias(es)
EVEC, UP50, DANCE, ARMD3

Chromosome
14q32.12

Zygosity of Responsible Variant
Heterozygous

Mitochondrial Involvement
No

Variant Mechanism

Unknown

Details

Mechanistic basis:
Unresolved

Confidence:
Low

Prediction:
The literature stops short of a mechanism for CMT1H: the recurrent dominant missense allele alters fibulin-5, a secreted matrix glycoprotein that tethers lysyl oxidase-like enzymes to tropoelastin and organizes elastic fiber assembly. Since fibulin-5 multimerizes outside the cell, a mutant that is still secreted could disrupt assembly directly, whereas one retained inside would only reduce the protein available, and no study has determined which the CMT1H allele does.

Rationale:
Biallelic FBLN5 loss of function causes autosomal recessive cutis laxa rather than CMT, so the dominant nerve phenotype is not a simple reading of reduced fibulin-5. Whether the missense product reaches the matrix and interferes there, or never arrives at all, is the untested step on which the mechanism turns.

ClinVar Pathogenic Variants

View FBLN5 ClinVar Variants

CMT1H OMIM Entry

CMT1H OMIM

FBLN5 OMIM Entry

FBLN5 OMIM

More Info

CMT1H Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Demyelinating Charcot-Marie-Tooth Neuropathy Associated with FBLN5 Mutations

Authors

Safka Brozkova, D., Stojkovic, T., Haberlová, J., Mazanec, R., Windhager, R., Fernandes Rosenegger, P., Hacker, S., Züchner, S., Kochański, A., Leonard-Louis, S., Francou, B., Latour, P., Senderek, J., Seeman, P., & Auer-Grumbach, M.

Publication Date
August 5, 2020

Updated: May 9, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


A Name That Does Too Much Work

Jean-Martin Charcot's name appears throughout medicine, but nowhere does it create more confusion than in the foot. Learn why the CMT foot and Charcot neuroarthropathy, also known as Charcot foot, share a name yet differ in how they develop, appear, and are managed.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.